Dr. John Cush RheumNow
7 months ago
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025
https://t.co/yzQVt1fLKW https://t.co/hrbEeppZhW
Dr. John Cush RheumNow
7 months ago
APP Pearls “Point out to every patient with gout that poorly controlled gout will increase their risk of CV events and mortality” - Emma Bavage, NP
Dr. John Cush RheumNow
7 months ago
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
Dr. John Cush RheumNow
7 months ago
Best of 2025: Methotrexate intolerance in rheumatoid arthritis
Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week. https://t.co/hzfF7UVKVI
Dr. John Cush RheumNow
7 months ago
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis
The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/KacbtcMn5G
Dr. John Cush RheumNow
7 months ago
Algorithm for the treatment of calcinosis #calcinosis #ACR24 https://t.co/NZhP7Enzrp https://t.co/I0HLtYjzgb
Dr. John Cush RheumNow
7 months ago
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/PTJPhcvnzC
Dr. John Cush RheumNow
7 months ago
Best of 2025: Overview of the VEXAS Syndrome
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
https://t.co/O3BoOElcbT https://t.co/0hSEWqMFVf
Dr. John Cush RheumNow
7 months ago
Inflammatory vs. Noninflammatory Pain
https://t.co/ZZLMnT8IVO https://t.co/dnZHqV1jcK
Dr. John Cush RheumNow
7 months ago
Intro to ILD (Part I): the essentials
🫁 Definition & basics
🔬 Key pathology patterns
🧑⚕️ Clinical approach
📋 What rheums need to know
⬇️ Download & learn more: https://t.co/Fn76PiGsPl
Created by
@MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/JpyE3T7Atj
Dr. John Cush RheumNow
7 months ago
APP Pearls “Do not order a test if you do not know how to interpret the results whether normal or abnormal” - Madison Chastain, CRNP
Dr. John Cush RheumNow
7 months ago
Is the term polymyositis obsolete?.. now being replaced by dermatomyositis, necrotizing myopathy, inclusion body myositis, antisynthetase syndrome & overlap myositis. Full read overview of inflammatory myositis & new treatments from Joint Bone & Spine https://t.co/X46sptp1Ax https://t.co/M80026Z3Ur
Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.
Current guidelines recommend limiting the use of glucocorticoids by coining the new concept of “bridging therapy”, that is, use GCs when the disease is active and get rid of them as soon as you can. This way of thinking is conceptually attractive, however, the formula for translation to real life settings is not included.
